Navigation Links
Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood
Date:11/19/2007

f the hydrochlorothiazide component, AVALIDE is

contraindicated in patients with anuria or hypersensitivity to

sulfonamide-derived drugs

-- In patients with volume or sodium depletion (eg, patients vigorously

treated with diuretics or on dialysis), such depletion should be

corrected prior to administration of AVAPRO(R) (irbesartan) or

AVALIDE(R) (irbesartan-hydrochlorothiazide), or a lower initial dose of

AVAPRO (75 mg) should be used, to avoid possible symptomatic

hypotension

-- Hypersensitivity reactions to hydrochlorothiazide may occur in patients

with or without a history of allergy or bronchial asthma, but are more

likely in patients with such a history

-- Thiazide diuretics have been reported to cause exacerbation or

activation of systemic lupus erythematosus

-- Lithium generally should not be given with thiazides

-- Thiazides should be used with caution in patients with severe renal

disease and in patients with impaired hepatic function or progressive

liver disease, since minor alterations of fluid and electrolyte balance

may precipitate hepatic coma

-- In placebo-controlled hypertension studies, there were no significant

differences in adverse events (AEs) between AVAPRO and

placebo. Adverse events that occurred in at least 1% of patients

treated with AVAPRO and at a higher incidence vs placebo included

diarrhea (3% vs 2%), dyspepsia/heartburn (2% vs 1%) and fatigue (4% vs

3%)

-- Additionally, in a study of hypertensive type 2 diabetic patients with

renal disease (proteinuria greater than or equal to 900 mg/day), the

reported AEs for AVAPRO were similar to those seen in hypertension

studies, with the exception of an increased incidence of orthostatic

symptoms; AVAPRO compared to placebo (both groups received adjunc
'/>"/>

SOURCE Bristol-Myers Squibb Company
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors
2. New Study Supports Efficacy of Vagus Nerve Stimulation for Treatment-Resistant Depression
3. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
4. Five-Year Data From Taxus II Clinical Trial Highlights Safety and Efficacy of Taxus(R) Stent Compared to Bare-Metal Stent
5. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
6. Ortho Biotech Reiterates Confidence in PROCRIT(R) (Epoetin alfa) Safety and Efficacy When Used According to Label
7. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
8. New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy
9. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
10. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
11. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... PARIS , Sept. 30, 2014 ... and NYSE: SNY) today announced that a Phase 2a ... IL-4 and IL-13 signaling, met all primary and secondary ... polyps (CSwNP) who did not respond to intranasal corticosteroids. ... dupilumab for use in the treatment of another allergic ...
(Date:9/29/2014)... PHILADELPHIA , Sept. 29, 2014  Repeated exposure ... life is associated with early childhood obesity, say researchers ... in a retrospective study based on data from ... The researchers found that children with ... infancy were particularly more likely to be at risk ...
(Date:9/29/2014)... DIEGO , 29 septembre 2014 ... (TSE : 4568) et Ambit Biosciences (NASDAQ : AMBI), ont ... fusion définitif en vertu duquel Daiichi Sankyo fera ... circulation d,Ambit Biosciences à 15 dollars par action ... d,achat qui sera suivie d,une fusion avec une ...
Breaking Medicine Technology:Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps 2Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps 3Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps 4Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps 5Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps 6Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps 7Antibiotic Use by Age 2 Associated with Obesity Risk 2Antibiotic Use by Age 2 Associated with Obesity Risk 3Daiichi Sankyo va acquérir Ambit Biosciences 2Daiichi Sankyo va acquérir Ambit Biosciences 3Daiichi Sankyo va acquérir Ambit Biosciences 4Daiichi Sankyo va acquérir Ambit Biosciences 5Daiichi Sankyo va acquérir Ambit Biosciences 6Daiichi Sankyo va acquérir Ambit Biosciences 7Daiichi Sankyo va acquérir Ambit Biosciences 8Daiichi Sankyo va acquérir Ambit Biosciences 9
... AUSTIN, Texas, May 24, 2011 A paper published ... demonstrated that adding OVA1 to a physician,s preoperative ... ovarian cancers than a physician,s preoperative assessment alone. The ... the journal, which is the official publication of the ...
... Holdings, Inc. (OTCQB: ABHI), a leader in the development of ... has signed a new line of credit with East West ... to expire July 2011. The new line of credit expands ... the previous revolving line and extends the line by one ...
Cached Medicine Technology:OVA1 Improves Ovarian Cancer Detection Over CA 125 Blood Test and Clinical Assessment 2OVA1 Improves Ovarian Cancer Detection Over CA 125 Blood Test and Clinical Assessment 3OVA1 Improves Ovarian Cancer Detection Over CA 125 Blood Test and Clinical Assessment 4AmbiCom Renews and Expands Line of Credit With East West Bank 2AmbiCom Renews and Expands Line of Credit With East West Bank 3
(Date:9/30/2014)... 30, 2014 Influenza is a significant ... can improve the efficacy of therapy, minimize overuse of ... disease in healthcare settings. Diagnostic tests available today vary ... The decision your laboratory makes in selecting the correct ... providers, is key to effective use of influenza diagnostics. ...
(Date:9/30/2014)... 3M has added four new thin VHB ... 3M 5906 , 3M 5907 , 3M ... which help create the strongest bond possible to a wide ... bonding to difficult surfaces such as paints, low surface energy ... and 5905 are designed specifically for electronic device engineers and ...
(Date:9/30/2014)... Seniors Guide will take part in running ... in Raleigh, to support Alzheimer’s North Carolina (AlzNC) in ... , Associate Publisher of Seniors Guide Magazine, Shannon Tippette, ... for the Raleigh-Durham-Chapel Hill areas of North Carolina for ... helping their team, “Eye of the Tiger”, reach their ...
(Date:9/30/2014)... 30, 2014 American Medical ID and ... agreement to raise awareness about Alzheimer’s disease and related ... people with these brain disorders. , American Medical ID ... AFA to the foundation to support its efforts to ... The ID bracelets and necklaces can be purchased via ...
(Date:9/30/2014)... Charlestown, RI (PRWEB) September 30, 2014 Dogs ... owner. Oftentimes, this involves spending time in the car travelling ... their canines have free run of the vehicle; however, this ... the owner as well. Royal Flush Havanese shares ... should always be routine practice. , There are many ways ...
Breaking Medicine News(10 mins):Health News:Alere Webinar Spotlights Optimal Flu Diagnostics to Keep Your Lab Ahead of the Curve 2Health News:Alere Webinar Spotlights Optimal Flu Diagnostics to Keep Your Lab Ahead of the Curve 3Health News:3M Releases New VHB™ Thin Foam Tapes as the Ultimate Electronics Bonding Solution 2Health News:3M Releases New VHB™ Thin Foam Tapes as the Ultimate Electronics Bonding Solution 3Health News:Seniors Guide To Run in 203 Mile Alzheimer’s Awareness Relay in Raleigh, North Carolina 2Health News:Seniors Guide To Run in 203 Mile Alzheimer’s Awareness Relay in Raleigh, North Carolina 3Health News:American Medical ID and Alzheimer’s Foundation of America Team up to Increase Awareness about Alzheimer’s Disease and Related Dementias 2Health News:American Medical ID and Alzheimer’s Foundation of America Team up to Increase Awareness about Alzheimer’s Disease and Related Dementias 3Health News:Royal Flush Havanese Offers Tops On the Importance of Restraining Dogs In Cars 2Health News:Royal Flush Havanese Offers Tops On the Importance of Restraining Dogs In Cars 3
... in circuits that regulate serotonin in certain parts of the ... cocaine-seeking, based on mouse studies published online this week in ... "The impetus for this research was our interest in ... in ways that lead to mood changes, depression, anxiety, and ...
... cuts conception rate, study found , THURSDAY, Oct. 29 ... minutes after being artificially inseminated greatly boost their odds ... treated for subfertility with IUI [intrauterine insemination] to remain ... chance at conceiving," said Inge Custers, lead author of ...
... ... Me Not Flower Club ("FMN-FC") today announced the launch of its online floral gift ... as well as other diseases associated with aging. , ... Camarillo, California (PRWEB) October 30, 2009 -- In ...
... expert offers tips for those thrown off schedule by Daylight ... That extra hour of sleep you,ll get in most parts ... the beginning of Daylight Saving Time could spell trouble for ... Atul Malhotra, medical director of the sleep disorders research program ...
... expectant moms led to bigger, healthier infants, studies show ... women head the list of people who should get ... new studies highlight the benefits of vaccination for moms-to-be ... births and reduced rates of hospitalization top the findings, ...
... , VIRGINIA BEACH, Va., Oct. 30, 2009 AMERIGROUP Corporation (NYSE: ... quarter of 2009 was $22.5 million, or $0.43 per diluted share, ... quarter of 2008. Third quarter earnings are in line with ... October 26, 2009, and reflect elevated medical costs associated ...
Cached Medicine News:Health News:Stress-induced changes in brain circuitry linked to cocaine relapse 2Health News:Stress-induced changes in brain circuitry linked to cocaine relapse 3Health News:Lying Still Raises Artificial Insemination Success 2Health News:Lying Still Raises Artificial Insemination Success 3Health News:Forget-Me-Not-Flower-Club Launches Floral Gift Program For Caregivers: Alzheimer's Awareness Month Program Offers Resources, Recognition for Friends and Family 2Health News:Forget-Me-Not-Flower-Club Launches Floral Gift Program For Caregivers: Alzheimer's Awareness Month Program Offers Resources, Recognition for Friends and Family 3Health News:When Clocks Change, Body May Need Time to Adjust 2Health News:Flu Shot in Pregnancy Protects Baby 2Health News:Flu Shot in Pregnancy Protects Baby 3Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 2Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 3Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 4Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 5Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 6Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 7Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 8Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 9Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 10Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 11Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 12Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 13Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 14Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 15Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 16Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 17Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 18
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: